Compound

• US 7,960,551 B2
• Filed: 02/08/2007
• Issued: 06/14/2011
• Est. Priority Date: 02/10/2006
• Status: Active Grant

• Current Assignee: Theravance Biopharma R&D IP, LLC (Theravance Biopharma, Inc.)
• Original Assignee: Glaxo Group Limited (Glaxosmithkline Holdings Ltd.)
• Inventors: Kennedy, Andrew, Chudasama, Reshma
• Primary Examiner(s): Seaman; D. Margaret
• Application Number:
  US11/672,536
• Publication Number:
  US 20070281971A1
• Time in Patent Office: 1,587 Days
• Field of Search: 546/159, 514/312
• US Class Current: 546/159
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 11/06 Antiasthmatics
• CPC Class Codes: A61P 11/08 Bronchodilators
• CPC Class Codes: A61P 11/16 Central respiratory analeptics
• CPC Class Codes: C07D 401/12 linked by a chain containing hetero atoms as chain links

Abstract

A succinic acid salt of biphenyl-2-ylcarbamic acid 1-[2-(2-chloro-4-{[(R)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethylamino]methyl}-5-methoxyphenylcarbamoyl)ethyl]piperidin-4-yl ester or a solvate thereof, for use in treating pulmonary disorders.

Claims

1. A succinic acid salt of biphenyl-2-ylcarbamic acid 1-[2-(2-chloro-4-{[(R)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethylamino]methyl}-5-methoxyphenylcarbamoyl)ethyl]piperidin-4-yl ester, which is the Form 1 crystalline solid state form, wherein said salt is characterized by an x-ray powder diffraction pattern having diffraction peaks at 2θ

values of 5.0±

0.3 and 10.0±

0.3.

2. The salt of claim 1, wherein the salt is further characterized by:

(a) a differential scanning calorimetry trace which shows a melting point in the range of about 170°

C. to about 180°

C.;

or

(b) an infrared absorption spectrum with significant absorption bands at about 3265, 2832, 1735, 1718, 1679, 1669, 1591, 1540, 1518, 1493, 1439, 1405, 1339, 1302, 1283, 1239, 1202, 1163, 1144, 1107, 1095, 1039, 1009, 973, 921, 885, 868, 838, 773, 751, and 707 cm<sup>−

1</sup>.

3. The salt of claim 1 which is in micronized form.

4. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a salt of claim 1.

5. The pharmaceutical composition of claim 4, wherein the composition further comprises a steroidal anti-inflammatory agent.

6. The pharmaceutical composition of claim 5, wherein the steroidal anti-inflammatory agent is 6α

,9α

-difluoro-17α

-[(2-furanylcarbonyl)oxy]-11β

-hydroxy-16α

-methyl-3-oxoandrosta-1,4-diene-17β

-carbothioic acid S-fluoromethyl ester.

7. The pharmaceutical composition of claim 5, wherein the steroidal anti-inflammatory agent is fluticasone propionate.

8. The pharmaceutical composition of claim 4, in micronized form.

9. The pharmaceutical composition of claim 4, wherein the carrier is selected from the group consisting of lactose, starch, mannitol, dextrose, polylactic acid, polylactide-co-glycolide and a combination thereof.

10. A combination comprising:

(a) a salt of claim 1; and

(b) a steroidal anti-inflammatory agent.

11. The combination of claim 10, wherein the steroidal anti-inflammatory agent is 6α

,9α

-difluoro-17α

-[(2-furanylcarbonyl)oxy]-11β

-hydroxy-16α

-methyl-3-oxoandrosta-1,4-diene-17β

-carbothioic acid S-fluoromethyl ester.

12. The combination of claim 10, wherein the steroidal anti-inflammatory agent is fluticasone propionate.

13. A method of producing bronchodilation in a patient, the method comprising administering to the patient a bronchodilation-producing amount of a salt of claim 1.

14. A method of treating chronic obstructive pulmonary disorder or asthma, the method comprising administering to a patient in need of treatment a therapeutically effective amount of a salt of claim 1.

15. A process for preparing the Form 1 succinate salt according to claim 1, which process comprises the steps:

dissolving the succinate salt in aqueous THF, at a temperature in the range 18 to 23°

C., adding a first volume of a lower alcohol to the aqueous THF;

heating the aqueous THF to 32-40°

C.;

optionally seeding with Form 1;

adding a second volume of the lower alcohol to the heated aqueous THF,

cooling to the aqueous THF to a temperature in the range 18 to 23°

C. to form a crystallized product; and

collecting the crystalline product.